- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
HLTH Inc. and GE Healthcare Reveal Healthcare-Themed Art Gallery
The gallery will be a part of the HLTH Europe event and will be open to all attendees.
No More Barriers
Doug Healy
Healthcare brings out the artist in pharma.
HLTH Inc. announced its own art gallery, sponsored by GE HealthCare. In a press release, HLTH Inc. revealed that the gallery will be part of its inaugural HLTH Europe event, which will occur from June 17-20, 2024 in Amsterdam. The gallery will be open throughout the entire event and will be available to all attendees.
In a press release, HLTH Europe’s managing director Katy Fryatt said, “We are thrilled to launch the HLTH Europe Art Gallery with the support of the GE HealthCare team. Art is a powerful medium through which we can share our experiences and connect with each other. We encourage submissions from all stakeholders in the healthcare ecosystem from patient groups to care givers, clinicians and system leaders. The gallery will foster a sense of community among the whole healthcare ecosystem through art. Ultimately, we hope the gallery offers a reminder about why we are coming together at HLTH–for the benefit of patients."
HLTH is accepting submissions for the gallery from HCPs, patients, and caregivers. The gallery will include a variety of mediums, including paintings, digital art, and photography. Attendees of the gallery will also have access to interactive workshops on various visual art methods.
Simon Philip Rost, Chief Marketing Officer Enterprise Imaging, GE HealthCare, says, "We are proud to be part of this initiative at HLTH Europe. We recognise the therapeutic power of art and its contribution to patients' holistic wellbeing and would encourage everyone in the healthcare ecosystem to consider submitting their work. We look forward to providing a creative outlet for patients and healthcare professionals alike later this year in Amsterdam."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
